ME02689B - Novi kristalni oblik iii agomelatina, postupak za njegovu pripremu i farmaceutski preparati istog - Google Patents
Novi kristalni oblik iii agomelatina, postupak za njegovu pripremu i farmaceutski preparati istogInfo
- Publication number
- ME02689B ME02689B MEP-2017-33A MEP3317A ME02689B ME 02689 B ME02689 B ME 02689B ME P3317 A MEP3317 A ME P3317A ME 02689 B ME02689 B ME 02689B
- Authority
- ME
- Montenegro
- Prior art keywords
- disorders
- form iii
- accordance
- production
- agomelatine
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 3
- 239000013078 crystal Substances 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims 3
- 229960002629 agomelatine Drugs 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000027559 Appetite disease Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 230000001193 melatoninergic effect Effects 0.000 claims 1
- 239000000155 melt Substances 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (5)
1. Kristalni oblik III agomelatina formule (I): naznačen time, da je praćen dijagramom rendgenske difrakcijske zraka, mjeren uporabom Siemens D5005matik difraktometra (bakarna antikatoda) i izražen interplanarnom razdaljinom d, Braggovog kuta 2 teta i relativnim intenzitetom (izraženim u postocima u odnosu na najintenzivniju crtu): 2-Teta (°) izr. d (Å) izr. Intenzitet (%) 10.52 12.92 16.15 17.38 17. 84 18.55 19.20 19.89 20.32 21.15 22.08 22.96 23.33 23.84 24.52 24.88 25.07 26.27 26.86 27.97 29.51 8.405 6.848 5.482 5.097 4.968 4.779 4.619 4.460 4.366 4.197 4.022 3.870 3.810 3.730 3.628 3.576 3.550 3.390 3.316 3.187 3.024 100 40 53 69 96 22 97 30 24 26 16 23 95 33 25 59 90 61 22 20 43
2. Postupak za pripravu kristalnog oblika III spoja formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da se agomelatin izlaže temperature do 110°C dok se potpuno ne rastopi, nakon čega se polagano hladi dok se ponovo ne kristalizira.
3. Farmaceutski pripravci koji sadrže djelatni sastojak kristalnog oblika III agomelatina u skladu s patentnim zahtjevom 1, naznačeno time, da je u kombinaciji s jednim ili više intertnih, netoksičnih, farmaceutski prihvatljivih nosača.
4. Farmaceutski pripravci u skladu s patentnim zahtjevom 3, naznačeni time, da se koriste u proizvodnji lijekova za liječenje poremećaja melatoninergičkog sustava.
5. Farmaceutski pripravci u skladu s patentnim zahtjevom 3, naznačeni time, da se koriste u proizvodnji lijekova za liječenje poremećaja spavanja, stresa, anksioznosti, sezonskih depresija ili teške depresije, kardiovaskularnih patologija, patologija probavnog sustava, nesanice i umora uslijed vremenske razlike nakon letenja (jet-lag), shizofrenije, napadaja panike, melankolije, poremećaja apetita, pretilosti, nesanice, psihotičkih poremećaja, epilepsije, dijabetesa, Parkinsonove bolesti, senilne demencija, raznih poremećaja povezanih s uobičajenim ili patološkim starenjem, migrene, gubitka pamćenja, Alzheimerove bolesti, poremećaja moždane cirkulacije, također i seksualne disfunkcije, kao inhibitori ovulacije i imunomodulatori i u liječenju karcinoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0508276A FR2889521B1 (fr) | 2005-08-03 | 2005-08-03 | Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| EP10003436.2A EP2210872B1 (fr) | 2005-08-03 | 2006-08-02 | Nouvelle forme cristalline iii de l'agomélatine, son procédé de préparation et les compositions pharmaceutiques qui la contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02689B true ME02689B (me) | 2017-10-20 |
Family
ID=36587257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-33A ME02689B (me) | 2005-08-03 | 2006-08-02 | Novi kristalni oblik iii agomelatina, postupak za njegovu pripremu i farmaceutski preparati istog |
Country Status (35)
| Country | Link |
|---|---|
| EP (3) | EP1752445A1 (me) |
| JP (1) | JP4580370B2 (me) |
| CN (1) | CN100450995C (me) |
| AR (1) | AR057713A1 (me) |
| AU (1) | AU2006203336B2 (me) |
| BR (1) | BRPI0603074A (me) |
| CA (1) | CA2555117A1 (me) |
| CY (1) | CY1118637T1 (me) |
| DK (1) | DK2210872T3 (me) |
| EA (1) | EA011031B1 (me) |
| ES (1) | ES2614934T3 (me) |
| FR (1) | FR2889521B1 (me) |
| GE (1) | GEP20094576B (me) |
| GT (1) | GT200600347A (me) |
| HR (1) | HRP20170095T1 (me) |
| HU (1) | HUE030506T2 (me) |
| JO (1) | JO3360B1 (me) |
| LT (1) | LT2210872T (me) |
| MA (1) | MA28449B1 (me) |
| ME (1) | ME02689B (me) |
| MX (1) | MXPA06008790A (me) |
| MY (1) | MY142856A (me) |
| NO (1) | NO337010B1 (me) |
| NZ (1) | NZ548862A (me) |
| PE (1) | PE20070213A1 (me) |
| PL (1) | PL2210872T3 (me) |
| PT (1) | PT2210872T (me) |
| RS (1) | RS55499B1 (me) |
| SA (1) | SA06270253B1 (me) |
| SG (1) | SG130112A1 (me) |
| SI (1) | SI2210872T1 (me) |
| TW (1) | TWI389873B (me) |
| UA (1) | UA83719C2 (me) |
| WO (1) | WO2007015003A2 (me) |
| ZA (1) | ZA200606454B (me) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2934856B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede d'obtention de la forme cristalline v de l'agomelatine |
| CN101585779B (zh) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
| WO2011006387A1 (zh) * | 2009-07-11 | 2011-01-20 | 浙江华海药业股份有限公司 | 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法 |
| CN102001959B (zh) * | 2009-09-01 | 2014-07-02 | 北京本草天源药物研究院 | 一种药物晶体及其制备方法和用途 |
| CN102050755B (zh) * | 2009-10-29 | 2014-11-05 | 重庆医药工业研究院有限责任公司 | 阿戈美拉汀的晶型及其制备方法 |
| CN101709036B (zh) * | 2009-12-17 | 2012-07-04 | 天津药物研究院 | 阿戈美拉汀中间体2-(7-甲氧基-1-萘基)乙胺的制备 |
| CN101781226B (zh) | 2009-12-23 | 2012-03-28 | 天津泰普药品科技发展有限公司 | 阿戈美拉汀及其药物组合物 |
| CN101774937B (zh) * | 2010-02-05 | 2014-01-08 | 天津市汉康医药生物技术有限公司 | N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺及其组合物 |
| CL2011001405A1 (es) | 2010-06-10 | 2012-03-30 | Gador S A Conicet | Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina. |
| CZ303787B6 (cs) * | 2011-01-21 | 2013-05-02 | Zentiva, K.S. | Metastabilní krystalové formy agomelatinu a jejich farmaceutické kompozice |
| CN102690210A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物 |
| CN102690209A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 |
| FR2978916B1 (fr) | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| WO2013082302A1 (en) | 2011-11-30 | 2013-06-06 | Ratiopharm Gmbh | Agomelatine-urea complex and crystalline forms thereof |
| CZ2012108A3 (en) | 2012-02-15 | 2013-02-27 | Zentiva Ks | A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine |
| WO2014096373A1 (en) | 2012-12-21 | 2014-06-26 | Laboratorios Lesvi, S. L. | Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof |
| FR3001894A1 (fr) | 2013-02-08 | 2014-08-15 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
| ES2645223T3 (es) | 2013-06-06 | 2017-12-04 | Zentiva, K.S. | Formulaciones de agomelatina que comprenden agomelatina en forma de co-cristales |
| CZ2013621A3 (cs) | 2013-08-13 | 2015-02-25 | Zentiva, K.S. | Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci |
| WO2015124496A1 (en) | 2014-02-19 | 2015-08-27 | Synthon B.V. | Pharmaceutical composition comprising amorphous agomelatine |
| PL3075724T3 (pl) | 2015-03-31 | 2023-12-27 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Stała postać agomelatyny |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2866335B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
| FR2866336B1 (fr) * | 2004-02-13 | 2006-03-24 | Servier Lab | Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine |
-
2005
- 2005-08-03 FR FR0508276A patent/FR2889521B1/fr not_active Expired - Lifetime
-
2006
- 2006-07-19 PE PE2006000866A patent/PE20070213A1/es not_active Application Discontinuation
- 2006-07-24 JO JOP/2006/0245A patent/JO3360B1/ar active
- 2006-07-24 MA MA29210A patent/MA28449B1/fr unknown
- 2006-07-31 GT GT200600347A patent/GT200600347A/es unknown
- 2006-08-01 SG SG200605175-9A patent/SG130112A1/en unknown
- 2006-08-01 NZ NZ548862A patent/NZ548862A/en not_active IP Right Cessation
- 2006-08-01 SA SA06270253A patent/SA06270253B1/ar unknown
- 2006-08-02 EP EP06291253A patent/EP1752445A1/fr not_active Withdrawn
- 2006-08-02 MY MYPI20063735A patent/MY142856A/en unknown
- 2006-08-02 ME MEP-2017-33A patent/ME02689B/me unknown
- 2006-08-02 PL PL10003436T patent/PL2210872T3/pl unknown
- 2006-08-02 UA UAA200608688A patent/UA83719C2/ru unknown
- 2006-08-02 AR ARP060103364A patent/AR057713A1/es not_active Application Discontinuation
- 2006-08-02 TW TW095128299A patent/TWI389873B/zh not_active IP Right Cessation
- 2006-08-02 EA EA200601274A patent/EA011031B1/ru not_active IP Right Cessation
- 2006-08-02 EP EP10003436.2A patent/EP2210872B1/fr active Active
- 2006-08-02 NO NO20063516A patent/NO337010B1/no not_active IP Right Cessation
- 2006-08-02 EP EP08017458A patent/EP2008993A1/fr not_active Withdrawn
- 2006-08-02 PT PT100034362T patent/PT2210872T/pt unknown
- 2006-08-02 WO PCT/FR2006/001868 patent/WO2007015003A2/fr not_active Ceased
- 2006-08-02 GE GEAP20069558A patent/GEP20094576B/en unknown
- 2006-08-02 SI SI200632141A patent/SI2210872T1/sl unknown
- 2006-08-02 RS RS20161179A patent/RS55499B1/sr unknown
- 2006-08-02 ES ES10003436.2T patent/ES2614934T3/es active Active
- 2006-08-02 HU HUE10003436A patent/HUE030506T2/en unknown
- 2006-08-02 DK DK10003436.2T patent/DK2210872T3/en active
- 2006-08-02 LT LTEP10003436.2T patent/LT2210872T/lt unknown
- 2006-08-03 CA CA002555117A patent/CA2555117A1/fr not_active Abandoned
- 2006-08-03 CN CNB2006101083967A patent/CN100450995C/zh not_active Expired - Fee Related
- 2006-08-03 MX MXPA06008790A patent/MXPA06008790A/es active IP Right Grant
- 2006-08-03 ZA ZA200606454A patent/ZA200606454B/xx unknown
- 2006-08-03 BR BRPI0603074-2A patent/BRPI0603074A/pt not_active Application Discontinuation
- 2006-08-03 JP JP2006211620A patent/JP4580370B2/ja not_active Expired - Fee Related
- 2006-08-03 AU AU2006203336A patent/AU2006203336B2/en not_active Ceased
-
2017
- 2017-01-20 HR HRP20170095TT patent/HRP20170095T1/hr unknown
- 2017-02-10 CY CY20171100190T patent/CY1118637T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170095T1 (hr) | Novi kristalni oblik iii agomelatina, postupak za njegovu pripravu i farmaceutski pripravci istog | |
| HRP20161672T1 (hr) | Novi kristalni oblik vi agomelatina, postupak priprave i farmaceutski pripravci istog | |
| HRP20120779T1 (hr) | Novi kristalni oblik v agomelatina, postupak za njegovu pripravu i farmaceutski pripravci koji ga sadrže | |
| ME02024B (me) | Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze | |
| DE69606915T2 (de) | Aryl(alkyl)propylamide, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten | |
| HRP20161647T1 (hr) | Novi sukristali agomelatina | |
| AU2006203340B2 (en) | New crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| CN104557588B (zh) | 咖啡酸和阿魏酸的同二聚体,其制备方法及其药物组合物 | |
| ME02731B (me) | Mješoviti kristalni oblik agomelatina. (oblik-viii), postupak pripreme i njegove primjene i farmaceutski pripravak koji ga sadrži | |
| US20060270877A1 (en) | Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| HRP20090632T1 (hr) | Novi derivati naftalena, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
| CN104860847B (zh) | 利凡斯的明和咖啡酸、阿魏酸的二聚体,其制备方法及其药物组合物 | |
| KR100904116B1 (ko) | 아고멜라틴의 ⅴ 결정형, 이의 제조 방법 및 이를 함유하는 약제 조성물 | |
| TH88290A (th) | ผลึกรูปแบบ iii ชนิดใหม่ของอะโกเมลาทีน, กรรมวิธีในการเตรียมและองค์ประกอบทางเภสัชกรรมซึ่งมีสารนี้ | |
| TH58747B (th) | ผลึกรูปแบบ iii ชนิดใหม่ของอะโกเมลาทีน, กรรมวิธีในการเตรียมและองค์ประกอบทางเภสัชกรรมซึ่งมีสารนี้ | |
| HRP20191119T1 (hr) | Ko-kristali agomelatina i p-toluensulfonske kiseline, način pripreme i i farmaceutski pripravci koji sadržavaju iste | |
| HRP20200927T1 (hr) | Kompleksi agomelatina i sulfonskih kiselina, postupak njihove proizvodnje i proizvodnje farmaceutskih pripravaka koji ih sadržavaju | |
| HK1098128B (en) | New crystalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| HK1098129B (en) | New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| HK1131777B (en) | Crystalline form vi of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| HK1098130B (en) | New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| TH74932B (th) | ผลึกรูปแบบ IV ชนิดใหม่ของอะโกเมลาทีน (agomelatine), กระบวนการสำหรับการเตรียมของสารนี้ และองค์ประกอบทางเภสัชกรรมที่มีสารนี้อยู่ | |
| TH88291A (th) | ผลึกรูปแบบ IV ชนิดใหม่ของอะโกเมลาทีน (agomelatine), กระบวนการสำหรับการเตรียมของสารนี้ และองค์ประกอบทางเภสัชกรรมที่มีสารนี้อยู่ | |
| HK1178881A1 (en) | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |